Abbott Laboratories

ABT

Medical - Devices · Healthcare

Price

$116.64

+2.50 (+2.19%)

Market Cap

$201.83B

Exchange

United States

Winston Score

Winston is curious

Mixed quality — meaningful strengths and weaknesses.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Mixed

Cash Flow

Exceptional

Stability

Strong

Valuation

Good

Dividends

Good

Track this stock — start free trial

Share count falling — buybacks

−2.3% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 1.79B (2021) → 1.75B (2025)

Winston Score History

The full picture

Abbott Laboratories makes medical products that help doctors diagnose and treat patients. Its main businesses include medical devices like heart stents and continuous glucose monitors (sold under the FreeStyle Libre brand), diagnostic tests used in hospitals and labs, and nutritional products like Similac baby formula and Ensure. Abbott sells to hospitals, clinics, pharmacies, and everyday consumers around the world.

Abbott earns money by selling physical products — devices, test kits, and nutrition products — across more than 160 countries. It is a large, diversified healthcare company with roughly $20 billion in annual revenue, and its scale and well-known brands give it a durable competitive position. The FreeStyle Libre glucose monitor is a fast-growing product in the expanding diabetes management market, but Abbott faces real competition from rivals like Dexcom in that space, and any product safety issues — as seen with its 2022 baby formula recall — can cause significant financial and reputational damage.

Politician Trades

65 trades / 12mo

23 Congressional buys and 41 sells on ABT in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+13.0% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-48.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$3.0B/ year

→ Flat (+5% vs prior year)

6.7% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

0.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$8.4B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

Abbott Laboratories is a rare growth stock that's already generating positive cash flow while growing at 13%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

58.0%

Premium pricing power — 58.0% gross margin

Profit after running costs

Operating Margin

14.2%

Healthy — 14.2% operating margin

Return on the money invested

ROCE

9.2%

Below par — 9.2% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+8.1%

Steady sales growth (+8.1% YoY)

Profit growth

EPS YoY

-61.4%

Earnings shrinking (-61.4% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

174%

Turns 174% of profit into real cash

Spare cash per sale

FCF Margin

15.8%

Converts sales into free cash efficiently (15.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.65

Moderate — manageable debt (0.65)

Covers its interest

Interest Cover

12.45x

Comfortably covers interest (12.5x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

37.5x

Pricey — P/E 37.5

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+21.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (37.5 → 16.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.30%

Moderate income — 2.30% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+6.9%

Dividend growing modestly (6.9% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial